Structure Therapeutics (NASDAQ:GPCR) Trading Down 4.6% - Here's Why

Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) shares were down 4.6% during mid-day trading on Tuesday . The company traded as low as $23.56 and last traded at $23.42. Approximately 114,349 shares changed hands during trading, a decline of 88% from the average daily volume of 929,190 shares. The stock had previously closed at $24.55.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on GPCR shares. William Blair started coverage on Structure Therapeutics in a research report on Friday, February 28th. They set an "outperform" rating on the stock. HC Wainwright cut their target price on Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating on the stock in a research note on Monday, May 12th. Finally, Citigroup began coverage on shares of Structure Therapeutics in a research note on Friday, May 2nd. They set a "buy" rating and a $60.00 price target for the company. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Structure Therapeutics currently has an average rating of "Buy" and a consensus target price of $79.86.

Structure Therapeutics Price Performance

The firm has a market capitalization of $1.25 billion, a P/E ratio of -29.35 and a beta of -1.69. The company has a fifty day moving average of $21.69 and a 200 day moving average of $25.50.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.03). On average, sell-side analysts forecast that Structure Therapeutics Inc. will post -0.82 EPS for the current year.

Institutional Trading of Structure Therapeutics

Several large investors have recently modified their holdings of GPCR. Barclays PLC grew its position in shares of Structure Therapeutics by 64.5% during the 3rd quarter. Barclays PLC now owns 81,138 shares of the company's stock worth $3,562,000 after buying an additional 31,815 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Structure Therapeutics by 10.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 12,634 shares of the company's stock worth $343,000 after purchasing an additional 1,174 shares in the last quarter. Spire Wealth Management bought a new position in shares of Structure Therapeutics in the 4th quarter worth $243,000. CCG Wealth Management LLC bought a new position in shares of Structure Therapeutics in the 4th quarter worth $4,068,000. Finally, Money Concepts Capital Corp lifted its holdings in shares of Structure Therapeutics by 4.2% in the 4th quarter. Money Concepts Capital Corp now owns 21,031 shares of the company's stock worth $570,000 after purchasing an additional 848 shares in the last quarter. Institutional investors and hedge funds own 91.78% of the company's stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.